Literature DB >> 12375266

Genomic gain of PIK3CA and increased expression of p110alpha are associated with progression of dysplasia into invasive squamous cell carcinoma.

Joachim Woenckhaus1, Klaus Steger, Eva Werner, Irina Fenic, Ulrike Gamerdinger, Thomas Dreyer, Ulrich Stahl.   

Abstract

PIK3CA, encoding the catalytic subunit p110alpha of phosphatidylinositol 3-kinase (PI3K), is activated in malignant diseases. However, the role of the PIK3CA gene aberrations for tumourigenesis of head and neck squamous cell carcinoma (HNSCC) is to date unclear. The present study was designed to determine the genomic aberration of PIK3CA in invasive HNSCC and dysplastic precursor lesions by fluorescence in situ hybridization (FISH) with a YAC probe, containing the PIK3CA gene, on isolated interphase nuclei from histomorphologically well-defined regions of formalin-fixed tissue sections and to compare these data with protein and mRNA expression of p110alpha. The mRNA and protein levels of p110alpha were assessed, respectively, by in situ hybridization and immunohistochemistry on consecutive tissue sections. Copy number gains at 3q26 were observed in one of six low-to-moderate dysplasias (17%) and in seven of nine high-grade dysplasias (78%), as well as in 11 carcinomas (100%). In addition, one of seven high-grade dysplasias (14%) and 6 of 11 carcinomas (55%) had amplifications of 3q26. The majority of cases with copy number gain in more than 50% of the cells and/or amplification in more than 10% of cells showed increased p110alpha mRNA and protein expression, whereas only two cases (18%) (one high-grade dysplasia and one carcinoma) with no gain or low-level gain displayed increased p110alpha protein expression. These data suggest that 3q26 copy number gain and amplification represent early genomic aberrations in HNSCC carcinogenesis. In addition, p110alpha mRNA and protein expression in HNSCC may be regulated by these genomic aberrations as well as by epigenetic events. Copyright 2002 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12375266     DOI: 10.1002/path.1207

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  51 in total

1.  PIK3CA polymorphisms associated with susceptibility to hepatocellular carcinoma.

Authors:  Hong-Guang Li; Fang-Feng Liu; Hua-Qiang Zhu; Xu Zhou; Jun Lu; Hong Chang; Jin-Hua Hu
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

Review 2.  Dysregulated molecular networks in head and neck carcinogenesis.

Authors:  Alfredo A Molinolo; Panomwat Amornphimoltham; Cristiane H Squarize; Rogerio M Castilho; Vyomesh Patel; J Silvio Gutkind
Journal:  Oral Oncol       Date:  2008-09-19       Impact factor: 5.337

3.  The chromosome 3q26 OncCassette: A multigenic driver of human cancer.

Authors:  Alan P Fields; Verline Justilien; Nicole R Murray
Journal:  Adv Biol Regul       Date:  2015-12-23

4.  The determinants of head and neck cancer: Unmasking the PI3K pathway mutations.

Authors:  Fernanda S Giudice; Cristiane H Squarize
Journal:  J Carcinog Mutagen       Date:  2013-08-02

Review 5.  Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer.

Authors:  Mingzhao Xing
Journal:  Thyroid       Date:  2010-07       Impact factor: 6.568

6.  Novel mutant-enriched sequencing identified high frequency of PIK3CA mutations in pharyngeal cancer.

Authors:  Wanglong Qiu; Guo-Xia Tong; Spiros Manolidis; Lanny G Close; Adel M Assaad; Gloria H Su
Journal:  Int J Cancer       Date:  2008-03-01       Impact factor: 7.396

Review 7.  Lessons learned from next-generation sequencing in head and neck cancer.

Authors:  Myriam Loyo; Ryan J Li; Chetan Bettegowda; Curtis R Pickering; Mitchell J Frederick; Jeffrey N Myers; Nishant Agrawal
Journal:  Head Neck       Date:  2012-08-21       Impact factor: 3.147

8.  PIK3CA mutations in head and neck squamous cell carcinoma.

Authors:  Wanglong Qiu; Frank Schönleben; Xiaojun Li; Daniel J Ho; Lanny G Close; Spiros Manolidis; Boyce P Bennett; Gloria H Su
Journal:  Clin Cancer Res       Date:  2006-03-01       Impact factor: 12.531

Review 9.  Targeting PI3K signalling in cancer: opportunities, challenges and limitations.

Authors:  Jeffrey A Engelman
Journal:  Nat Rev Cancer       Date:  2009-08       Impact factor: 60.716

10.  SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas.

Authors:  Adam J Bass; Hideo Watanabe; Craig H Mermel; Soyoung Yu; Sven Perner; Roel G Verhaak; So Young Kim; Leslie Wardwell; Pablo Tamayo; Irit Gat-Viks; Alex H Ramos; Michele S Woo; Barbara A Weir; Gad Getz; Rameen Beroukhim; Michael O'Kelly; Amit Dutt; Orit Rozenblatt-Rosen; Piotr Dziunycz; Justin Komisarof; Lucian R Chirieac; Christopher J Lafargue; Veit Scheble; Theresia Wilbertz; Changqing Ma; Shilpa Rao; Hiroshi Nakagawa; Douglas B Stairs; Lin Lin; Thomas J Giordano; Patrick Wagner; John D Minna; Adi F Gazdar; Chang Qi Zhu; Marcia S Brose; Ivan Cecconello; Ulysses Ribeiro; Suely K Marie; Olav Dahl; Ramesh A Shivdasani; Ming-Sound Tsao; Mark A Rubin; Kwok K Wong; Aviv Regev; William C Hahn; David G Beer; Anil K Rustgi; Matthew Meyerson
Journal:  Nat Genet       Date:  2009-10-04       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.